What is a stock summary page? Click here for an overview.
Business Description
HOOKIPA Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US43906K1007
Description
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 45.35 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.12 | |||||
| Beneish M-Score | 0.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -14.6 | |||||
| 3-Year EBITDA Growth Rate | 46.6 | |||||
| 3-Year EPS without NRI Growth Rate | 49.6 | |||||
| 3-Year FCF Growth Rate | 36.4 | |||||
| 3-Year Book Growth Rate | -32.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.63 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.3 | |||||
| 9-Day RSI | 36.75 | |||||
| 14-Day RSI | 34.45 | |||||
| 3-1 Month Momentum % | -7.12 | |||||
| 6-1 Month Momentum % | -60.89 | |||||
| 12-1 Month Momentum % | -75.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.27 | |||||
| Quick Ratio | 3.27 | |||||
| Cash Ratio | 1.61 | |||||
| Days Sales Outstanding | 18.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.5 | |||||
| Shareholder Yield % | 9.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -85.08 | |||||
| Net Margin % | -98.99 | |||||
| FCF Margin % | -175.61 | |||||
| ROE % | -53.91 | |||||
| ROA % | -34.83 | |||||
| ROIC % | -133.41 | |||||
| 3-Year ROIIC % | -176.11 | |||||
| ROC (Joel Greenblatt) % | -451.25 | |||||
| ROCE % | -46.2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.35 | |||||
| PB Ratio | 0.28 | |||||
| Price-to-Tangible-Book | 0.28 | |||||
| EV-to-EBIT | 0.55 | |||||
| EV-to-EBITDA | 0.59 | |||||
| EV-to-Revenue | -0.55 | |||||
| EV-to-Forward-Revenue | 0.33 | |||||
| EV-to-FCF | 0.31 | |||||
| Price-to-GF-Value | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 0.3 | |||||
| Price-to-Net-Cash | 1.75 | |||||
| Earnings Yield (Greenblatt) % | 181.82 | |||||
| FCF Yield % | -528.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HOOK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HOOKIPA Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 43.946 | ||
| EPS (TTM) ($) | -3.51 | ||
| Beta | 0.78 | ||
| 3-Year Sharpe Ratio | -0.93 | ||
| 3-Year Sortino Ratio | -1.2 | ||
| Volatility % | 51.25 | ||
| 14-Day RSI | 34.45 | ||
| 14-Day ATR ($) | 0.128804 | ||
| 20-Day SMA ($) | 1.33225 | ||
| 12-1 Month Momentum % | -75.25 | ||
| 52-Week Range ($) | 1.11 - 10.5 | ||
| Shares Outstanding (Mil) | 12.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HOOKIPA Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HOOKIPA Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
HOOKIPA Pharma Inc Frequently Asked Questions
What is HOOKIPA Pharma Inc(HOOK)'s stock price today?
The current price of HOOK is $1.21. The 52 week high of HOOK is $10.50 and 52 week low is $1.11.
When is next earnings date of HOOKIPA Pharma Inc(HOOK)?
The next earnings date of HOOKIPA Pharma Inc(HOOK) is 2025-05-09 Est..
Does HOOKIPA Pharma Inc(HOOK) pay dividends? If so, how much?
HOOKIPA Pharma Inc(HOOK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers